Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Phase III Study With OncoVEX (GM-CSF) in Head and Neck Cancer
Date:9/15/2009

WOBURN, Mass., Sept. 15 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating its lead product, OncoVEX (GM-CSF), for the first-line treatment of patients with squamous cell cancer of the head and neck.

The study is the second the Company has agreed with the FDA under the Special Protocol Assessment (SPA) procedure and highlights the broad potential utility of BioVex's first-in-class cancer destroying virus technology. The first SPA was in melanoma under which BioVex is currently conducting a pivotal Phase III trial.

Patients with head and neck cancer often present with locally advanced, bulky disease that is too large, or too close, to vital organs to remove surgically. These patients typically undergo combination radiation and chemotherapy treatment, in some cases with additional surgery. Patients who present with tumor-containing lymph nodes are particularly difficult to treat and approximately half of these patients relapse within two years.

Philip Astley-Sparke, President & CEO, for BioVex said:

"The announcement of our second SPA governing a Phase III study demonstrates the breadth of the commercial opportunity with OncoVEX (GM-CSF). In addition to treating metastatic disease as is the intention in our ongoing Phase 3 study in melanoma, following multiple systemic responses in Phase II, OncoVEX (GM-CSF) also has considerable potential utility in treating discrete solid tumor masses across multiple indications including those that are poorly served by radiation. As with tumors like head and neck cancer where loco-regional progression is the primary cause of treatment failure, treating discrete tu
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
2. BioVex Raises $40 Million in First Close of Series F Financing
3. BioVex to Present at the UBS Global Life Sciences Conference
4. BioVex Closes Second Round of Series E Financing
5. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
8. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... Patients , Study will provide new insights on mechanics of fecal microbiota transplantation ... new partnership to study the microbiome of patients undergoing fecal microbiota transplantation (FMT) ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of shares proposed ... common shares (including shares of unvested restricted stock). On June 29, 2015, the last ... of Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. , The tender ...
(Date:6/30/2015)... , June 30, 2015  Custom Computer Specialists, ... today that they are silver sponsors of the Primary ... PCDC sponsor, Custom is lending their support of PCDC,s ... communities. Since its founding in 1993, PCDC ... primary care area.  PCDC has financed over 100 completed ...
(Date:6/30/2015)... ... 30, 2015 , ... Southern Illinois University Edwardsville Chancellor Julie ... president of instruction at Chippewa Valley Technical College (CVTC) and will assume her ... lead SIUE during the past three years,” Furst-Bowe said. “I want to thank ...
Breaking Biology Technology:uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3
... driving second new office opening in North Carolina in last 12 ... ... N.C., Jan. 17 Quintiles,Transnational Corp. today announced that the global leader ... an expansion of Quintiles, clinical research in pharmaceutical,and biotechnology development., The ...
... Board to advise on cancer screening methods and ... mitochondrial DNA-based disease detection, ... TBIO) today announced that it has formed a Scientific,Advisory ... and,scientific opportunities in cancer detection screening and mitochondrial,disease diagnosis. ...
... Advancement Towards Creating Patient-Specific and Disease-Specific ... Stem Cells For Therapeutic Use, LA ... research company, announced today it has become the,first in the world ... nuclear transfer (SCNT)., Stemagen CEO Samuel H. Wood, M.D., Ph.D., ...
Cached Biology Technology:Quintiles to Open Clinical Research Office in Wilmington, NC 2Transgenomic, Inc. Forms Scientific Advisory Board 2Transgenomic, Inc. Forms Scientific Advisory Board 3Stemagen First to Create Cloned Human Embryos From Adult Cells 2Stemagen First to Create Cloned Human Embryos From Adult Cells 3
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... previously communicated that it will amount to at least 340 ... Due to the rapid increase in market growth and orders ... previously communicated guidance that revenue for 2015 will exceed 1,500 ... amount to approximately 2,200 MSEK. Due to receipt ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... patent to electronically capture, analyze and identify participants ... recognition methods. This system can: ... an enrollment and subsequent sign-on process is actually ...
(Date:6/9/2015)... 2015 Research and Markets  ( http://www.researchandmarkets.com/research/xsgs2s/gesture ... "Gesture Recognition & Touchless Sensing Market by Technology ... Others), Product (Biometric & Sanitary Equipment) & by ... to their offering. The total gesture ... reach $ 23.55 Billion by 2020 at a ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... the University of Bonn, working in collaboration with scientists ... previously unknown regulatory mechanism in the process of bone ... the treatment of osteoporosis. More than four million people, ... illness in Germany alone. In recognition of the importance ...
... L-arginine following a heart attack does not improve certain ... an increased risk of death, according to a study ... is a widely available dietary supplement and is publicized ... failure and sexual dysfunction, according to background information in ...
... The discovery of a possible hibernation hormone in the ... researchers reported in the April 7, 2006 issue of ... survive unscathed--in a state of suspended animation--under the harshest ... are confirmed, the hormone would represent the first essential ...
Cached Biology News:New weapon in battle against osteoporosis 2New weapon in battle against osteoporosis 3An elephant tail 2Possible brain hormone may unlock mystery of hibernation 2Possible brain hormone may unlock mystery of hibernation 3
RABBIT ANTI RAT AQUAPORIN 5...
... 0.2 and 2.0 mL samples for freezing point determinations. Includes built-in printer, ... capability with optional scanner. RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 alpha, CF...
Biology Products: